Research Output per year
Research Output 2003 2019
- 1 - 50 out of 72 results
- Publication Year, Title (descending)
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Stein, M., Goodin, S., Gounder, M., Gibbon, D., Moss, R., Portal, D., Lindquist, D., Zhao, Y., Takebe, N., Tan, A., Aisner, J., Lin, H., Ready, N. & Mehnert, J., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.Research output: Contribution to journal › Article
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
Mehnert, J., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J., Gibbon, D., Doyle, L. A., White, E. & Stein, M., Jan 1 2019, (Accepted/In press) In : Cancer chemotherapy and pharmacology.Research output: Contribution to journal › Article
Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial
Keilholz, U., Mehnert, J., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.Research output: Contribution to journal › Article
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
Andtbacka, R. H. I., Amatruda, T., Nemunaitis, J., Zager, J. S., Walker, J., Chesney, J. A., Liu, K., Hsu, C. P., Pickett, C. A. & Mehnert, J., Sep 1 2019, In : EBioMedicine. 47, p. 89-97 9 p.Research output: Contribution to journal › Article
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 others, , Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.Research output: Contribution to journal › Article
Cytokine Therapy
Silk, A. & Margolin, K., Apr 1 2019, In : Hematology/Oncology Clinics of North America. 33, 2, p. 261-274 14 p.Research output: Contribution to journal › Review article
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
D’Angelo, S. P., Hunger, M., Brohl, A. S., Nghiem, P., Bhatia, S., Hamid, O., Mehnert, J., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Schlichting, M., Hennessy, M. H. & Bharmal, M., Apr 2 2019, In : Cancer Immunology, Immunotherapy. 68, 4, p. 609-618 10 p.Research output: Contribution to journal › Article
Erratum to: Autophagy maintains tumour growth through circulating arginine (Nature, (2018), 563, 7732, (569-573), 10.1038/s41586-018-0697-7)
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J., Guo, Y., Lattime, E., Rabinowitz, J. D. & White, E., Jan 3 2019, In : Nature. 565, 7737, p. E3Research output: Contribution to journal › Comment/debate
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing
Boussemart, L., Nelson, A., Wong, M., Ross, J. S., Sosman, J., Mehnert, J., Daniels, G., Kendra, K., Ali, S. M., Miller, V. A. & Schrock, A. B., May 2019, In : Oncologist. 24, 5, p. 657-663 7 p.Research output: Contribution to journal › Review article
Interferon Lambda: Toward a Dual Role in Cancer
Lasfar, A., Zloza, A., Silk, A., Lee, L. & Cohen-Solal, K. A., Jan 1 2019, In : Journal of Interferon and Cytokine Research. 39, 1, p. 22-29 8 p.Research output: Contribution to journal › Article
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
Chesney, J., Puzanov, I., Collichio, F., Milhem, M. M., Hauschild, A., Chen, L., Sharma, A., Garbe, C., Singh, P. & Mehnert, J., Aug 27 2019, In : British Journal of Cancer. 121, 5, p. 417-420 4 p.Research output: Contribution to journal › Article
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
Varga, A., Piha-Paul, S., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Yang, P., Ruman, J. & Matei, D., Feb 2019, In : Gynecologic Oncology. 152, 2, p. 243-250 8 p.Research output: Contribution to journal › Article
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma
Portal, D. E., Weiss, R. E., Wojtowicz, M., Mansour, A., Monken, C., Mehnert, J. M., Aisner, J. A., Kane, M., Nishioka, J., Aisner, S., Peters, S., Stein, M. N., Kim, I. Y., Mayer, T. M., Shih, W., Gulley, J., Streicher, H., Singer, E. A. & Lattime, E. C., Jan 1 2019, In : Cancer gene therapy.Research output: Contribution to journal › Article
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: A multicenter, retrospective case series
Lopiccolo, J., Schollenberger, M. D., Dakhil, S., Rosner, S., Ali, O., Sharfman, W. H., Silk, A. W., Bhatia, S. & Lipson, E. J., Jul 8 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 170.Research output: Contribution to journal › Article
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C. C., Prawira, A., De Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., Gilbert, J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Keam, B., Mar 4 2019, In : BMC cancer. 19, 1, 196.Research output: Contribution to journal › Article
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028
Ott, P. A., Bang, Y. J., Piha-Paul, S. A., Abdul Razak, A. R., Bennouna, J., Soria, J. C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J., Lopez, J., Doi, T., van Brummelen, E. M. J., Cristescu, R., Yang, P., Emancipator, K., Stein, K., Ayers, M., Joe, A. K. & Lunceford, J. K., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 318-327 10 p.Research output: Contribution to journal › Article
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. & McDermott, D. F., Feb 18 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 49.Research output: Contribution to journal › Article
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L., Gajewski, T. F., Gastman, B., Lawson, D. H., Lutzky, J., McDermott, D. F., Margolin, K. A., Mehnert, J. M., Pavlick, A. C., Richards, J. M., Rubin, K. M., Sharfman, W., Silverstein, S., Slingluff, C. L. & 8 others, , May 30 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 44.Research output: Contribution to journal › Article
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Mehnert, J., Edelman, G., Stein, M., Camisa, H., Lager, J., Dedieu, J. F., Ghuysen, A. F., Sharma, J., Liu, L. & LoRusso, P. M., Feb 1 2018, In : Investigational New Drugs. 36, 1, p. 36-44 9 p.Research output: Contribution to journal › Article
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
Mehnert, J. M., Silk, A. W., Lee, J. H., Dudek, L., Jeong, B. S., Li, J., Schenkel, J. M., Sadimin, E., Kane, M., Lin, H., Shih, W. J., Zloza, A., Chen, S. & Goydos, J. S., Jul 2018, In : Pigment Cell and Melanoma Research. 31, 4, p. 534-540 7 p.Research output: Contribution to journal › Article
Autophagy maintains tumour growth through circulating arginine
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J., Guo, Y., Lattime, E., Rabinowitz, J. D. & White, E., Nov 22 2018, In : Nature. 563, 7732, p. 569-573 5 p.Research output: Contribution to journal › Letter
Immune activation and benefit from avelumab in EBV-positive gastric cancer
Panda, A., Mehnert, J., Hirshfield, K., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M., Poplin, E., Rodriguez-Rodriguez, L., Silk, A., Aisner, J., Chan, N., Malhotra, J., Frankel, M., Kaufman, H. L., Ali, S., Ross, J. S., White, E. P. & 2 others, , Mar 1 2018, In : Journal of the National Cancer Institute. 110, 3, p. 316-320 5 p.Research output: Contribution to journal › Article
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Hurwitz, M. E., Markowski, P., Yao, X., Deshpande, H., Patel, J., Mortazavi, A., Donadio, A., Stein, M., Kelly, W. K., Petrylak, D. P. & Mehnert, J., Dec 1 2018, In : Clinical Genitourinary Cancer. 16, 6, p. 437-444.e6Research output: Contribution to journal › Article
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Ascierto, P. A., Puzanov, I., Agarwala, S. S., Bifulco, C., Botti, G., Caracò, C., Ciliberto, G., Davies, M. A., Dummer, R., Ferrone, S., Gajewski, T. F., Garbe, C., Luke, J. J., Marincola, F. M., Masucci, G., Mehnert, J. M., Mozzillo, N., Palmieri, G., Postow, M. A., Schoenberger, S. P. & 2 others, , Jul 21 2018, In : Journal of translational medicine. 16, 1, 207.Research output: Contribution to journal › Article
Phase IB results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer
Krishnamurthy, A., Dasari, A., Noonan, A. M., Mehnert, J. M., Lockhart, A. C., Leong, S., Capasso, A., Stein, M. N., Sanoff, H. K., Lee, J. J., Hansen, A., Malhotra, U., Rippke, S., Gustafson, D. L., Pitts, T. M., Ellison, K., Davis, S. L., Messersmith, W. A., Eckhardt, S. G. & Lieu, C. H., Sep 15 2018, In : Cancer Research. 78, 18, p. 5398-5407 10 p.Research output: Contribution to journal › Article
Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., Egan, J. O., Jones, M., Rhode, P. R., Rock, A. D., Cheever, M. A., Wong, H. C. & Ernstoff, M. S., Nov 15 2018, In : Clinical Cancer Research. 24, 22, p. 5552-5561 10 p.Research output: Contribution to journal › Article
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study
Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M. & Soria, J. C., Jan 1 2018, In : Obstetrical and Gynecological Survey. 73, 1, p. 26-27 2 p.Research output: Contribution to journal › Comment/debate
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Kelly, K., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., May 1 2018, In : Cancer. 124, 9, p. 2010-2017 8 p.Research output: Contribution to journal › Article
BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAFV600E mutant melanoma
Kulkarni, A., Al-Hraishawi, H., Simhadri, S., Hirshfield, K. M., Chen, S., Pine, S., Jeyamohan, C., Sokol, L., Ali, S., Teo, M. L., White, E., Rodriguez-Rodriguez, L., Mehnert, J. M. & Ganesan, S., Sep 15 2017, In : Clinical Cancer Research. 23, 18, p. 5631-5638 8 p.Research output: Contribution to journal › Article
First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors
Stein, M., Bertino, J., Kaufman, H. L., Mayer, T., Moss, R., Silk, A., Chan, N., Malhotra, J., Rodriguez-Rust, L., Aisner, J., Aiken, R., Haffty, B., DiPaola, R. S., Saunders, T., Zloza, A., Damare, S., Beckett, Y., Yu, B., Najmi, S., Gabel, C. & 7 others, , Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4163-4169 7 p.Research output: Contribution to journal › Article
Immuno-oncology clinical trial design: Limitations, challenges, and opportunities
Baik, C. S., Rubin, E. H., Forde, P. M., Mehnert, J. M., Collyar, D., Butler, M. O., Dixon, E. L. & Chow, L. Q. M., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4992-5002 11 p.Research output: Contribution to journal › Article
Intratumoral Approaches for the Treatment of Melanoma
Bommareddy, P. K., Silk, A. & Kaufman, H. L., Jan 1 2017, In : Cancer Journal (United States). 23, 1, p. 40-47 8 p.Research output: Contribution to journal › Review article
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Nov 21 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 95.Research output: Contribution to journal › Article
Oncolytic viruses-natural and genetically engineered cancer immunotherapies
Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W. & Zloza, A., Sep 11 2017, In : Frontiers in Oncology. 7, SEP, 202.Research output: Contribution to journal › Review article
Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study
Ott, P. A., Elez, E., Hiret, S., Kim, D. W., Morosky, A., Saraf, S., Piperdi, B. & Mehnert, J., Dec 1 2017, In : Journal of Clinical Oncology. 35, 34, p. 3823-3829 7 p.Research output: Contribution to journal › Article
Pseudoprogression of a spinal metastasis after stereotactic ablative body radiation therapy and immune checkpoint therapy
Jhawar, S. R., Silk, A. & Goyal, S., Mar 1 2017, In : Practical Radiation Oncology. 7, 2, p. 109-112 4 p.Research output: Contribution to journal › Article
Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study
Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M. & Soria, J. C., Aug 1 2017, In : Journal of Clinical Oncology. 35, 22, p. 2535-2541 7 p.Research output: Contribution to journal › Article
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
Hsu, C., Lee, S. H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J., Algazi, A., Van Brummelen, E. M. J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Hansen, A. R., Dec 20 2017, In : Journal of Clinical Oncology. 35, 36, p. 4050-4056 7 p.Research output: Contribution to journal › Article
The challenge for development of valuable immuno-oncology biomarkers
Mehnert, J., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L. & Harris, L. N., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4970-4979 10 p.Research output: Contribution to journal › Article
A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer
Stein, M. N., Hussain, M., Stadler, W. M., Liu, G., Tereshchenko, I. V., Goodin, S., Jeyamohan, C., Kaufman, H. L., Mehnert, J. & Dipaola, R. S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. 22-27 6 p.Research output: Contribution to journal › Article
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A., Ganesan, S., Kaufman, H. L. & Mehnert, J., Jan 1 2016, In : American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 35, p. e493-e503Research output: Contribution to journal › Article
Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers
Hirshfield, K., Tolkunov, D., Zhong, H., Ali, S. M., Stein, M., Murphy, S., Vig, H., Vazquez, A., Glod, J., Moss, R. A., Belyi, V., Chan, C., Chen, S., Goodell, L., Foran, D., Yelensky, R., Palma, N. A., Sun, J. X., Miller, V. A., Stephens, P. J. & 10 others, , Nov 1 2016, In : Oncologist. 21, 11, p. 1315-1325 11 p.Research output: Contribution to journal › Article
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., Fu, Y. X., Gajewski, T. F., Garbe, C., Huber, V., Khleif, S., Krauthammer, M., Lo, R. S., Masucci, G., Palmieri, G., Postow, M. & 16 others, , Nov 15 2016, In : Journal of translational medicine. 14, 1, 313.Research output: Contribution to journal › Article
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Schadendorf, D., Dummer, R., Hauschild, A., Robert, C., Hamid, O., Daud, A., van den Eertwegh, A., Cranmer, L., O'Day, S., Puzanov, I., Schachter, J., Blank, C., Salama, A., Loquai, C., Mehnert, J. M., Hille, D., Ebbinghaus, S., Kang, S. P., Zhou, W. & Ribas, A., Nov 1 2016, In : European Journal of Cancer. 67, p. 46-54 9 p.Research output: Contribution to journal › Article
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M., Rodriguez-Rodriquez, L., Kaufman, H. L., Ali, S., Ross, J. S., Pavlick, D. C., Bhanot, G., White, E., DiPaola, R. S., Lovell, A., Cheng, J. & Ganesan, S., Jun 1 2016, In : Journal of Clinical Investigation. 126, 6, p. 2334-2340 7 p.Research output: Contribution to journal › Article
Importance of including patients with comorbidities in clinical trials
Spencer, K. R. & Mehnert, J., Jan 1 2016, In : The Lancet Oncology. 17, 1, p. 17-18 2 p.Research output: Contribution to journal › Comment/debate
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Rehman, H., Silk, A. W., Kane, M. P. & Kaufman, H. L., Sep 20 2016, In : Journal for ImmunoTherapy of Cancer. 4, 1, 53.Research output: Contribution to journal › Article
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J., Sosman, J. A., Long, G. V. & 1 others, , Feb 1 2016, In : JAMA Oncology. 2, 2, p. 234-240 7 p.Research output: Contribution to journal › Article
Mucosal melanoma: Epidemiology, biology and treatment
Spencer, K. R. & Mehnert, J., Jan 1 2016, Cancer Treatment and Research. Kluwer Academic Publishers, p. 295-320 26 p. (Cancer Treatment and Research; vol. 167).Research output: Chapter in Book/Report/Conference proceeding › Chapter
Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma
Xie, X., Koh, J. Y., Price, S., White, E. & Mehnert, J. M., Apr 1 2015, In : Cancer Discovery. 5, 4, p. 410-423 14 p.Research output: Contribution to journal › Article